Open access
Open access
Powered by Google Translator Translator

Pharmacology/Pharmaceutical Industry

M-A: Association of tranexamic acid administration with mortality and thromboembolic events in patients with traumatic injury.

3 Mar, 2022 | 07:57h | UTC

Association of Tranexamic Acid Administration With Mortality and Thromboembolic Events in Patients With Traumatic Injury: A Systematic Review and Meta-analysis – JAMA Network Open

Related:

M-A: Prehospital Tranexamic Acid reduces mortality among bleeding trauma patients without increasing the risk of venous thromboembolism.

Tranexamic acid after traumatic brain injury: Exploratory analysis combining data from CRASH-2 and CRASH-3 trials suggests reduced mortality

Meta-analysis: Efficacy and safety of tranexamic acid in acute traumatic brain injury

Randomized trial: Tranexamic acid during prehospital transport in patients at risk for hemorrhage after injury

Randomized trial: Out-of-hospital tranexamic acid does not improve neurologic outcomes in patients with traumatic brain injury

Editorial: Is Tranexamic Acid Going to CRASH the Management of Traumatic Brain Injury?

Practice-Changing: Tranexamic Acid Reduces the Risk of Head Injury-related Death in Patients with Mild-to-moderate Head Injury

 

M-A: Evaluation of budesonide-formoterol for maintenance and reliever therapy among patients with poorly controlled asthma.

3 Mar, 2022 | 07:59h | UTC

Evaluation of Budesonide-Formoterol for Maintenance and Reliever Therapy Among Patients With Poorly Controlled Asthma: A Systematic Review and Meta-analysis – JAMA Network Open

 

Prescribing Nirmatrelvir–Ritonavir for Covid-19: How to recognize and manage drug–drug interactions.

2 Mar, 2022 | 09:01h | UTC

Prescribing Nirmatrelvir–Ritonavir: How to Recognize and Manage Drug–Drug Interactions – Annals of Internal Medicine

Related:

Statement on potential drug-drug interactions between Ritonavir-boosted Nirmatrelvir (Paxlovid) and concomitant medications; antiarrhythmics, oral anticoagulants, immunosuppressants, anticonvulsants, antineoplastics, and neuropsychiatric drugs are among the drugs of concern.

Pfizer antiviral pills may be risky with other medications – NBC News

The New COVID-19 Pill, Paxlovid, Interacts with Many Medications: Cardiac Patients Take Note – The Skeptical Cardiologist

 

[Preprint] Study shows significantly reduced effectiveness of the Pfizer vaccine in children 5 to 11 after the emergency of the Omicron variant.

1 Mar, 2022 | 08:54h | UTC

Effectiveness of the BNT162b2 vaccine among children 5-11 and 12-17 years in New York after the Emergence of the Omicron Variant – medRxiv

Commentaries:

Pfizer Covid vaccine is less effective in kids 5 to 11, study finds – STAT

Pfizer Covid-19 vaccine effectiveness fell quickly for kids during Omicron surge but still offered some protection against severe disease – CNN

More mask mandates fall as poor COVID vaccine protection noted in young kids – CIDRAP

 

Review: CRISPR in cancer biology and therapy.

27 Feb, 2022 | 22:27h | UTC

CRISPR in cancer biology and therapy – Nature Reviews Cancer (if the link is paywalled, try this one)

 

M-A: Fetal and maternal outcomes after maternal biologic use during conception and pregnancy.

25 Feb, 2022 | 10:43h | UTC

Fetal and maternal outcomes after maternal biologic use during conception and pregnancy: a systematic review and meta-analysis – BJOG

 

RCT: Two-week methotrexate discontinuation in patients with rheumatoid arthritis vaccinated with inactivated SARS-CoV-2 vaccine.

24 Feb, 2022 | 10:20h | UTC

Two-week methotrexate discontinuation in patients with rheumatoid arthritis vaccinated with inactivated SARS-CoV-2 vaccine: a randomised clinical trial – Annals of Rheumatic Diseases

Commentary: Suspend Methotrexate for RA Patients Getting COVID Vax?— It’s not a simple choice, Brazilian study suggests (free registration required)

 

[Preprint] Fourth dose of COVID vaccine offers only slight boost against Omicron infection.

24 Feb, 2022 | 10:30h | UTC

Fourth dose of COVID vaccine offers only slight boost against Omicron infection – Nature

Original Study: 4th Dose COVID mRNA Vaccines’ Immunogenicity & Efficacy Against Omicron VOC – medRxiv

 

Two large populational-based studies find a slightly increased risk of thrombotic events following AstraZeneca COVID-19 vaccination.

24 Feb, 2022 | 10:23h | UTC

Association of COVID-19 vaccines ChAdOx1 and BNT162b2 with major venous, arterial, or thrombocytopenic events: A population-based cohort study of 46 million adults in England – PLOS Medicine

See also: First dose ChAdOx1 and BNT162b2 COVID-19 vaccinations and cerebral venous sinus thrombosis: A pooled self-controlled case series study of 11.6 million individuals in England, Scotland, and Wales – PLOS Medicine

Commentaries:

Two studies find only small elevated risk of blood clots following AstraZeneca COVID-19 vaccination – PLOS

Two Large Studies Affirm Rare Thrombosis Risk With ChAdOx1 COVID-19 Vax – TCTMD

 

ASCO Report: Use of Biosimilar Medications in Oncology.

24 Feb, 2022 | 10:08h | UTC

Use of Biosimilar Medications in Oncology – JCO Oncology Practice

News Release: New ASCO Report Clarifies Potential Value and Utility of Biosimilars in Oncology – ASCO Daily News

 

USPSTF Draft Statement: Statin use for the primary prevention of cardiovascular disease in adults.

23 Feb, 2022 | 10:45h | UTC

Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: Preventive Medication – U.S. Preventive Services Task Force

Commentary: USPSTF Updates Guidance on Statins for Primary Prevention of CVD – HealthDay

 

RCT: Sublingual dexmedetomidine reduces mild to moderate acute agitation in patients with bipolar disorder.

23 Feb, 2022 | 10:18h | UTC

Effect of Sublingual Dexmedetomidine vs Placebo on Acute Agitation Associated With Bipolar Disorder: A Randomized Clinical Trial – JAMA (free for a limited period)

Editorial: Sublingual Dexmedetomidine as a Potential New Treatment for Agitation – JAMA (free for a limited period)

 

Commentary on Twitter

 

AGA clinical practice update on de-prescribing of proton pump inhibitors.

22 Feb, 2022 | 10:12h | UTC

AGA Clinical Practice Update on De-Prescribing of Proton Pump Inhibitors: Expert Review – Gastroenterology

Related:

Deprescribing proton pump inhibitors guideline

Review: Deprescribing Proton Pump Inhibitors

 

Meta-analysis finds low risk of a second allergic reaction to SARS-CoV-2 mRNA vaccines in patients with an allergic reaction with the first dose.

22 Feb, 2022 | 10:05h | UTC

Risk of Second Allergic Reaction to SARS-CoV-2 Vaccines: A Systematic Review and Meta-analysis – JAMA Internal Medicine

 

Commentary on Twitter

 

Opinion by Dr. Eric Topol | Why one-shot after a Covid-19 infection should suffice to be considered fully-vaxxed.

22 Feb, 2022 | 10:07h | UTC

Why one-shot after a Covid-19 infection should suffice to be considered fully-vaxxed – The Guardian

 

Commentary from the author on Twitter (thread – click for more)

 

[Preprint] A large-scale observational study in Chile found CoronaVac (an inactivated SARS-CoV-2 vaccine) was associated with an effectiveness of 74.5% against infection, 91.0% against hospitalization, and 93.8% against ICU admission in children aged 6 to 16 years.

22 Feb, 2022 | 09:58h | UTC

Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Children and Adolescents: A Large-Scale Observational Study – Preprints with The Lancet

Commentary: Full schedule of CoronaVac vaccine shown to be highly effective in children – News Medical

 

Monoclonal antibodies against rabies: current uses in prophylaxis and in therapy.

22 Feb, 2022 | 08:15h | UTC

Monoclonal antibodies against rabies: current uses in prophylaxis and in therapy – Current Opinion in Virology

 

RCT: In patients with mild to moderate Covid-19 and comorbidities, treatment with Ivermectin did not reduce the risk of disease progression.

21 Feb, 2022 | 09:34h | UTC

Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities: The I-TECH Randomized Clinical Trial – JAMA Internal Medicine

Commentaries:

Ivermectin doesn’t prevent severe disease from Covid-19, new study finds – CNN

Ivermectin futile for mild to moderate COVID-19, study finds – CIDRAP

Related:

Case Series: Toxic effects from ivermectin use associated with prevention and treatment of Covid-19.

Long-term consequences of the misuse of ivermectin data.

Ivermectin: How false science created a Covid ‘miracle’ drug.

Fraudulent ivermectin studies open up new battleground between science and misinformation.

The lesson of ivermectin: meta-analyses based on summary data alone are inherently unreliable.

Ivermectin: Cochrane’s most talked about review so far, ever. Why?

Flawed ivermectin preprint highlights challenges of COVID drug studies.

Systematic review: no evidence to support the use of Ivermectin for treating or preventing COVID-19.

Why was a major study on ivermectin for covid-19 just retracted?

RCT: Ivermectin does not prevent hospitalizations in patients with COVID-19.

Ivermectin for the treatment of COVID-19: A systematic review and meta-analysis of randomized controlled trials – “IVM did not reduce all-cause mortality, length of stay or viral clearance in RCTs in COVID-19 patients with mostly mild disease”.

Ivermectin is the new hydroxychloroquine, take 2 – “Ivermectin shouldn’t be used to treat COVID-19 outside of the context of a well-designed clinical trial”.

Therapeutics and COVID-19 | WHO guideline update advises Ivermectin should only be used to treat COVID-19 within clinical trials

RCT: Ivermectin does not improve time to resolution of symptoms among adults with mild COVID-19

 

Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis.

21 Feb, 2022 | 09:33h | UTC

Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis – International Journal of Infectious Diseases

 

RCT: Sub dissociative dose of ketamine with haloperidol vs. fentanyl on pain reduction in patients with acute pain in the emergency department.

21 Feb, 2022 | 08:37h | UTC

Sub dissociative dose of ketamine with haloperidol versus fentanyl on pain reduction in patients with acute pain in the emergency department; a randomized clinical trial – The American Journal of Emergency Medicine (link to abstract – $ for full-text)

 

New U.S. childhood and adolescent immunization schedule released by ACIP.

18 Feb, 2022 | 10:05h | UTC

Recommended Childhood and Adolescent Immunization Schedule: United States, 2022 – Pediatrics

See also:

Child and Adolescent Immunization Schedule: Recommendations for Ages 18 Years or Younger, United States, 2022 – Centers for Disease Control and Prevention

Advisory Committee on Immunization Practices Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger — United States, 2022 – CDC Morbidity and Mortality Weekly Report

 

New U.S. adult immunization schedule released by ACIP.

18 Feb, 2022 | 10:07h | UTC

Recommended Adult Immunization Schedule, United States, 2022 – Annals of Internal Medicine

News release: New adult immunization schedule recommends changes to zoster, pneumococcal, and hep B vaccines – American College of Physicians

See also: Adult Immunization Schedule: Recommendations for Ages 19 Years or Older, United States, 2022 – Centers for Disease Control and Prevention

 

RCT: Darolutamide and survival in metastatic, hormone-sensitive prostate cancer.

18 Feb, 2022 | 08:47h | UTC

Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer – New England Journal of Medicine

 

Commentary on Twitter

 

Cohort study: Protection against SARS-CoV-2 after Covid-19 vaccination lasts longer in patients with previous infection.

17 Feb, 2022 | 10:11h | UTC

Protection against SARS-CoV-2 after Covid-19 Vaccination and Previous Infection – New England Journal of Medicine

 

RCT: Oral Nirmatrelvir for high-risk adults with Covid-19 reduces the risk of hospitalization by 89%.

17 Feb, 2022 | 10:14h | UTC

Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19 – New England Journal of Medicine

Audio Interview: A New Antiviral against Covid-19 – new England Journal of Medicine

Related:

[Press release – not published yet] Pfizer’s Covid pill remains 89% effective for reducing the risk of hospitalization or death in final analysis.

[Press release – not published yet] RCT: Pfizer’s novel Covid-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis of phase 2/3 EPIC-HR study.

Statement on potential drug-drug interactions between Ritonavir-boosted Nirmatrelvir (Paxlovid) and concomitant medications; antiarrhythmics, oral anticoagulants, immunosuppressants, anticonvulsants, antineoplastics, and neuropsychiatric drugs are among the drugs of concern.

 

Commentary on Twitter

 

Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.